Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-Small Cell Lung Cancer

ClinicalTrials.gov ID: NCT01104155

Public ClinicalTrials.gov record NCT01104155. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 5, 2026, 10:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

The Purpose of This Study is to Investigate Two Different Dose Regimens of Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-small Cell Lung Cancer

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a Phase 2, multicenter, randomized study of two different dose regimens of eribulin mesylate in combination with intermittent erlotinib in patients with previously treated, advanced non-small cell lung cancer.

Study identification

NCT ID
NCT01104155
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Eisai Inc.
Industry
Enrollment
123 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 21, 2010
Primary completion
Apr 6, 2011
Completion
Jan 17, 2017
Last update posted
Jun 21, 2023

2010 – 2017

United States locations

U.S. sites
50
U.S. states
16
U.S. cities
50
Facility City State ZIP Site status
Not listed Bessemer Alabama
Not listed Birmingham Alabama
Not listed Beverly Hills California
Not listed La Jolla California
Not listed Aurora Colorado
Not listed Boulder Colorado
Not listed Colorado Springs Colorado
Not listed Denver Colorado
Not listed Lakewood Colorado
Not listed Littleton Colorado
Not listed Lone Tree Colorado
Not listed Longmont Colorado
Not listed Parker Colorado
Not listed Thornton Colorado
Not listed Washington D.C. District of Columbia
Not listed Ocala Florida
Not listed Port Saint Lucie Florida
Not listed Kansas City Kansas
Not listed Overland Park Kansas
Not listed Shawnee Mission Kansas
Not listed Detroit Michigan
Not listed Columbia Missouri
Not listed Jefferson City Missouri
Not listed Kansas City Missouri
Not listed Lee's Summit Missouri
Not listed St Louis Missouri
Not listed Las Vegas Nevada
Not listed Elizabeth City North Carolina
Not listed Portland Oregon
Not listed Tualatin Oregon
Not listed Philadelphia Pennsylvania
Not listed East Providence Rhode Island
Not listed Dallas Texas
Not listed Fort Worth Texas
Not listed Garland Texas
Not listed Plano Texas
Not listed Arlington Virginia
Not listed Chesapeake Virginia
Not listed Fairfax Virginia
Not listed Gainesville Virginia
Not listed Hampton Virginia
Not listed Leesburg Virginia
Not listed Newport News Virginia
Not listed Norfolk Virginia
Not listed Virginia Beach Virginia
Not listed Williamsburg Virginia
Not listed Winchester Virginia
Not listed Woodbridge Virginia
Not listed Spokane Washington
Not listed Vancouver Washington

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 14 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01104155, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 21, 2023 · Synced Sep 5, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01104155 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →